Duloxetine as adjunctive treatment of negative symptoms in patients with schizophrenia: a double blind and placebo controlled trial

Trial Profile

Duloxetine as adjunctive treatment of negative symptoms in patients with schizophrenia: a double blind and placebo controlled trial

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Duloxetine (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 New trial record
    • 22 Feb 2016 Primary endpoint of change in the PANSS negative subscale score from baseline to week 8 has not been met, according to results published in the Pharmacopsychiatry.
    • 22 Feb 2016 Results published in the Pharmacopsychiatry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top